Analysis of therapeutic effect of Sheng Xuexiaoban capsules on chemotherapy-related thrombocytopenia
Objective To investigate the population characteristics and clinical efficacy of Sheng Xuexiaoban capsules in the treatment of tumor chemotherapy-related thrombocytopenia(CIT)in the real word,and to observe its effectiveness and safety in a wide range of people,the rationality of clinical combination of drugs and the difference in efficacy of different combinations of drugs.Methods A retrospective study was conducted to select 2 812 CIT patients treated with Sheng Xuexiaoban capsules,and they were divided into four groups according to the combination of drugs,1 522 patients in treatment group A(Sheng Xuexiaoban capsules alone),719 patients in treatment group B(combined with recombinant human thrombopoietin injection),786 patients in treatment group C(combined with interleukin-11),and 9 patients in treatment group D(combined with hexapopethanolamine tablets).The changes of platelet count and CIT grade before and after the treatment were compared.Results Compared with before treatment,platelet counts in treatment groups A,B and C all increased after treatment,and the difference was statistically significant(P<0.001).In different treatment stages,the difference of CIT grading among the four groups was statistically significant(P<0.05).Conclusion Sheng Xuexiaoban capsules can significantly improve the platelet level of tumor chemotherapy-related thrombocytopenia,especially in combination with recombinant human thrombopoietin injection and interleukin-11,the overall safety is good,worthy of clinical promotion and application.
Sheng Xuexiaoban capsuleschemotherapy-induced thrombocytopeniareal world researchclinical efficacydrug combination